Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

J&J spinout readying first two Centyrin-oligo conjugates for the clinic

Led by CEO Susan Dillon, the J&J spinout prepares to advance its first two Centyrin-oligo conjugates to the clinic and grow its team.